Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of Adjuvanted Inactivated SARS-CoV-2 Vaccine in Healthy Adults
NCT04866069Phase 1Terminated
- Start
- Apr 2021
- Primary completion
- Sep 2021
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Covidful in coronavirus disease 2019 (COVID-19) (3 arms). Primary endpoints: Acute adverse events at 24 hours, Solicited local and systemic adverse events at 15 days and 1 more. Started Apr 2021; status: terminated.
02
Drugs
Covidful
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04866069.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04866069.